Glycoprotein News and Research

RSS

Aerosolized ACE2 neutralizes COVID-19 variants in lab and mice tests

Researchers from the University of Texas Southwestern have developed an aerosolized, mutated form of ACE2 that effectively neutralizes various SARS-CoV-2 variants in both cell cultures and mice. The study suggests that this modified ACE2 has promising preventive and therapeutic potential against COVID-19, especially with its easy aerosolized administration.

28 Sep 2023

The power of nanobodies: How they impact COVID-19 immune response

The structures of 340 antibodies (Abs) and 83 nanobodies.

25 Sep 2023

How are SARS-CoV-2 variants outsmarting our immune system and vaccines?

Researchers use multiomics analysis to understand how SARS-CoV-2 variants, including Alpha, Delta, and Omicron, modulate the host's cellular responses and adapt to evade human immunity. The study highlights the potential for targeted therapies against both adaptive and innate immune responses.

25 Sep 2023

Unlocking the power of mRNA vaccines: From COVID-19 to cancer and beyond

A comprehensive review in Signal Transduction and Targeted Therapy delves into the versatility and effectiveness of mRNA vaccines, from their game-changing role in COVID-19 to potential applications in cancer and rare diseases. Despite drawbacks like stability and high immunogenicity, advancements in vaccine technology have poised mRNA platforms as a robust tool for both preventive and therapeutic interventions.

21 Sep 2023

Unlocking the power of lectins: BOA emerges as a potent weapon against all SARS-CoV-2 variants

Researchers discover that antiviral lectins like BOA can effectively inhibit SARS-CoV-2 and its variants by targeting spike glycans, opening doors for potential pan-coronavirus treatments. The study reveals that BOA's multivalent interactions make it a potent inhibitor against a range of viral variants, offering promise for future therapeutic strategies.

14 Sep 2023

SARS-CoV-2 infection can exacerbate production of auto-antibodies relating to auto-immune diseases

An article published in NPJ Aging, a Springer Nature journal, reveals that natural production of auto-antibodies increases with age and that infection by SARS-CoV-2 can exacerbate production of auto-antibodies relating to auto-immune diseases, helping to explain why aging increases the chances of developing severe COVID-19.

12 Sep 2023

Breakthrough genome-wide study uncovers new loci impacting apolipoprotein E levels and Alzheimer's risk

New genetic factors that affect the plasma apolipoprotein E levels.

8 Sep 2023

Study characterizes SARS-CoV-2 Omicron BA.2.86: New variant under watch

Researchers identify a new SARS-CoV-2 variant, BA.2.86, with enhanced ability to evade immunity but lower infectivity compared to current variants. The study highlights the need for global monitoring due to its potential to become a predominant strain if it gains infectivity through mutations.

6 Sep 2023

Researchers characterize new SARS-CoV-2 BA.2.86 variant neutralization by monoclonal antibodies

Researchers used a SARS-CoV-2 spike protein-pseudotyped viral model to characterize BA.2.86 variant neutralization by monoclonal antibodies.

6 Sep 2023

Novavax's updated XBB.1.5 vaccine shows promising cross-neutralizing antibodies against new COVID-19 variants

The study reveals that Novavax's updated XBB.1.5 vaccine effectively induces cross-neutralizing antibodies against multiple Omicron XBB sub-variants in both mice and non-human primates.

5 Sep 2023

SARS-CoV-2 Eris variant spreads faster and dodges immunity

Study investigates the characteristics of the EG.5.1 "Eris" variant of SARS-CoV-2, finding it more transmissible among hamsters and slightly better at evading immunity compared to the XBB.1.5 variant. The results suggest that these properties could be driving the variant's increasing prevalence in human populations.

5 Sep 2023

Boosters slow antibody waning but hit a ceiling: Long-term COVID study reveals limits of immunity

The study tracks the long-term kinetics of antibody responses to SARS-CoV-2 after vaccination and infections in New York healthcare workers from 2020 to 2023. It reveals that antibody waning is slower after booster shots, but there's an upper limit to antibody levels, which gradually lowers with repeated SARS-CoV-2 exposures and vaccinations.

31 Aug 2023

Longer duration of anticoagulation therapy benefits cancer patients with isolated distal DVT

Twelve months of edoxaban is superior to three months for the reduction of thrombotic events in patients with cancer and distal deep vein thrombosis (DVT), according to late breaking research presented in a Hot Line session today at ESC Congress 2023.

29 Aug 2023

Epigenetic manipulation may improve breast cancer treatment responses

Researchers explore the possibility of increasing TROP2 ADC activity by enhancing the expression of TROP2 on cancer cells.

15 Aug 2023

Novel multi-epitope subunit vaccine induces robust immune response against Epstein-Barr virus

Scientists have developed a lymph node-targeted multi-epitope subunit vaccine that induces strong humoral and cellular immune responses against EBV in mice.

14 Aug 2023

Researchers discover possible new biomarker of MS-like autoimmune disease

It has been known for several years that the diagnosis "multiple sclerosis" conceals a whole range of different illnesses, each requiring customized treatment. Researchers at the University of Basel and the University Hospital of Basel have now described a possible new MS-like disease and explained how to diagnose it.

8 Aug 2023

Identification of plasma proteins associated with ovarian cancer risk

Can vitamin D have positive effects on reducing cortical pathology, oxidative stress, and neurofilament light chain serum levels?

Researchers use an established murine model of cortical inflammatory demyelination to investigate the effects of vitamin D.

2 Aug 2023